Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Operating Leases: 2019-2024

Historic Operating Leases for Autolus Therapeutics (AUTL) over the last 6 years, with Dec 2024 value amounting to $49.6 million.

  • Autolus Therapeutics' Operating Leases rose 26.05% to $65.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.8 million, marking a year-over-year increase of 26.05%. This contributed to the annual value of $49.6 million for FY2024, which is 6.30% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Operating Leases of $49.6 million as of FY2024, which was down 6.30% from $53.0 million recorded in FY2023.
  • Autolus Therapeutics' Operating Leases' 5-year high stood at $54.2 million during FY2020, with a 5-year trough of $21.0 million in FY2021.
  • Over the past 3 years, Autolus Therapeutics' median Operating Leases value was $49.6 million (recorded in 2024), while the average stood at $42.3 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Operating Leases tumbled by 61.23% in 2021, and later soared by 118.37% in 2023.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Operating Leases stood at $54.2 million in 2020, then tumbled by 61.23% to $21.0 million in 2021, then increased by 15.52% to $24.3 million in 2022, then surged by 118.37% to $53.0 million in 2023, then decreased by 6.30% to $49.6 million in 2024.